Novartis, Intellia expand collaboration for CRISPR/Cas9-based products

Intellia Therapeutics and Novartis are expanding their cell therapy collaboration agreement to include the ex vivo development of therapies using certain ocular stem cells, according to a press release.

Novartis will be able to use these stem cells to develop CRISPR/Cas9-based products under the agreement. Intellia will receive a one-time payment of $10 million, as well as be eligible for success-based milestones and royalties.

In addition, Intellia will gain extended rights to Novartis’ lipid nanoparticle technology for genome editing applications, the release said.

“Genome editing enhancements made by CRISPR/Cas9 will enable the next generation of cell therapies. With our collaborator, Novartis, we are broadening the ex vivo application of our CRISPR/Cas9 technology from hematopoietic stem cells, or HSCs, to ocular stem cells,” John Leonard, MD, Intellia CEO and president, said in the release.

Intellia Therapeutics and Novartis are expanding their cell therapy collaboration agreement to include the ex vivo development of therapies using certain ocular stem cells, according to a press release.

Novartis will be able to use these stem cells to develop CRISPR/Cas9-based products under the agreement. Intellia will receive a one-time payment of $10 million, as well as be eligible for success-based milestones and royalties.

In addition, Intellia will gain extended rights to Novartis’ lipid nanoparticle technology for genome editing applications, the release said.

“Genome editing enhancements made by CRISPR/Cas9 will enable the next generation of cell therapies. With our collaborator, Novartis, we are broadening the ex vivo application of our CRISPR/Cas9 technology from hematopoietic stem cells, or HSCs, to ocular stem cells,” John Leonard, MD, Intellia CEO and president, said in the release.